AccessibilityHelpAbout Us

Freenome(NASDAQ) FRNM

Market Cap$1.69BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+56%
5 YearN/A
1 Year+48%
1 Month+14%
$16.04
+2.17%
+0.34Today
After hours$15.85-$0.19 (-1.19%)
Freenome last closing stock price
MetricPriceDate
Last closeUSD 15.702026-09-23
Freenome stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.59%USD 14.732026-09-16
1 month+13.93%USD 13.782026-08-24
3 month+43.25%USD 10.962026-06-25
Year to date+20.49%USD 13.032025-12-31
1 year+48.11%USD 10.602025-09-23
Since inception+56.22%USD 10.052024-06-12

Freenome Financials at a Glance

Market Cap

$1.69BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$0.76

EPS (TTM)

-$0.07

P/E Ratio

-225.25

Dividend

$0.00

Beta (Volatility)

0.15 (Low)

Price

$16.04

Volume

414,533.206

Open

$15.57

Previous Close

$15.70

Daily Range

$15.28 - $16.06

52-Week Range

$9.95 - $17.50

Estimated Earnings Date

Dec 2, 2026

FRNM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Freenome

Freenome, Inc. is an innovative early cancer detection company focused on developing blood-based screening tests to identify cancer in its earliest and most treatable stages. Utilizing a proprietary multiomics discovery platform, Freenome analyzes circulating cell-free DNA methylation patterns alongside additional biomarkers to detect multiple cancers.

Products and Services
  • SimpleScreen CRC for colorectal cancer, currently under FDA review
  • Proprietary multiomics platform for comprehensive cancer detection
  • Focus on early-stage cancer identification to improve treatment outcomes
Growth Outlook
  • Strong market demand for early cancer detection solutions
  • Potential FDA approval could significantly enhance market presence
  • Expanding research collaborations to broaden product offerings
Financial Highlights
  • Market capitalization of approximately $134 million
  • Stock price range between $9.95 and $17.5 over the past year
  • Average trading volume of 750,672 shares, indicating solid investor interest
Freenome, Inc. operates in the Medical - Diagnostics & Research industry, with a focus on revolutionizing cancer detection through advanced technology. The company's first commercial-stage test, SimpleScreen CRC, is a significant step towards addressing the urgent need for effective cancer screening methods. With a strong market demand for early detection solutions and potential FDA approval on the horizon, Freenome is well-positioned for growth. The company's market capitalization and trading volume reflect a healthy interest from investors, indicating confidence in its innovative approach to cancer diagnostics.
AI Generated • Sep 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

Aaron Elliott, PhD

Website

www.perceptivelife.com/pcsc

Headquarters

Brisbane, CA 94005, US

FRNM Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-91.65%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-0.44%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$1.69BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

107.45M

Volume

414.53K

Avg. Volume

745.26K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Freenome Performance Analysis

Freenome annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Freenome annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD 0.17N/A
20252025-12-31USD 0.08-56.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$1.69BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$37.40

N/A

Employees

3

N/A

Net Income

-$0.11

-0.2%

EBITDA

-$0.94

+4.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$0.44

-67.5%

Total Debt

$0.00

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-86.06%

-0.2%

Return on Invested Capital

1.59%

+0.7%

Free Cash Flow

-$0.13

+0.9%

Operating Cash Flow

-$0.13

+0.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,699.60-0.00%
^DJIDJI
$51,363.06-0.00%
^IXICNASDAQ
$26,891.14-0.00%
BTCBitcoin
$84,410.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.32+82.65%
ONDSOndas
$7.61+2.77%
INTCIntel
$127.24+3.78%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.62-0.12%

Questions About FRNM

What is the current price of Freenome?

Freenome is trading at $16.00 per share.

What is the 52-week range for Freenome?

Over the past 52 weeks, Freenome has traded between $9.95 and $17.50.

How much debt does Freenome have?

As of the most recent reporting period, Freenome reported total debt of $0.00.

How much cash does Freenome have on hand?

Freenome reported $437.37K in cash and cash equivalents in its most recent financial results.

What is Freenome’s dividend yield?

Freenome does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services